While not seeing quite the productive year Dexcom has, diabetes-focused medical device developer Insulet has landed a number of wins so far this year. The company has seen its share value grow roughly 14.4% this year so far, closing at $43.09 on March 31.
The Billerica, Mass.–based company released the 1st data from the initial feasibility trial of its Omnipod Horizon closed-loop system for diabetes patients in February, touting consistent performance and minimal events of hypoglycemia.
The company also announced the opening of a new manufacturing facility in Acton, Mass., which it said will allow it to more efficiently produce its OmniPod system.
Insulet’s Omnipod system is a tubeless, wearable insulin delivery system which delivers the user up to 3 days of nonstop insulin. The system is compatible with all major continuous glucose monitoring systems, according to the company, and can be managed wirelessly with Insulet’s Personal Diabetes Management program.